MX2018001135A - Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble. - Google Patents

Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble.

Info

Publication number
MX2018001135A
MX2018001135A MX2018001135A MX2018001135A MX2018001135A MX 2018001135 A MX2018001135 A MX 2018001135A MX 2018001135 A MX2018001135 A MX 2018001135A MX 2018001135 A MX2018001135 A MX 2018001135A MX 2018001135 A MX2018001135 A MX 2018001135A
Authority
MX
Mexico
Prior art keywords
trifluoromethylphenyl
substituted
phenyl
epoxide hydrolase
analogs
Prior art date
Application number
MX2018001135A
Other languages
English (en)
Inventor
CODONY GISBERT Sandra
Valverde Murillo Elena
VÁZQUEZ CARRERA Manuel
Vázquez Cruz Santiago
Leiva Martínez Rosana
Original Assignee
Univ Barcelona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Barcelona filed Critical Univ Barcelona
Publication of MX2018001135A publication Critical patent/MX2018001135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

N-(2-oxaadamantan-1-il)ureas de fórmula I, donde R3 es H, alquilo C1-C3, ciclohexilo o fenilo; R es -[CH2]n-Y; n es 0-15; en -[CH2]n - 0-n/3 de los grupos metileno están opcionalmente sustituidos con átomos de oxígeno no adyacentes; e Y es un fenilo sustituido en 3 o 4, un ciclohexilo sustituido en 3 o 4, un piperidin-4-ilo sustituido en N, un piperidin-3-ilo sustituido en N, un fenilo di- o tri-fluorosustituido, 4-cloro-3-trifluorometilf enilo, 3-cloro-4-trifluorometilfenilo, 4-fluoro-3-trifluorometilfe nilo o 3-fluoro-4-trifluorometilfenilo; tienen actividades inhibidoras de epóxido hidrolasa (EHs) similares a aquellas de sus análogosde N-(adamantan-1-il)urea. Así, los compuestos I son útiles como API para el tratamiento de enfermedades mediadas por EHs. Además, en general, los compuestos I tienen solubilidades en agua más altas y puntos de fusión más bajos, que los hace más prometedores desde el punto de vista de la farmacocinética y formulación.(Ver fórmula I).
MX2018001135A 2015-07-28 2016-07-25 Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble. MX2018001135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178618 2015-07-28
PCT/EP2016/067620 WO2017017048A1 (en) 2015-07-28 2016-07-25 Analogs of adamantylureas as soluble epoxide hydrolase inhibitors

Publications (1)

Publication Number Publication Date
MX2018001135A true MX2018001135A (es) 2018-05-23

Family

ID=53758109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001135A MX2018001135A (es) 2015-07-28 2016-07-25 Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble.

Country Status (10)

Country Link
US (1) US20200079786A1 (es)
EP (1) EP3328854A1 (es)
KR (1) KR20180030706A (es)
CN (1) CN108349955A (es)
AU (1) AU2016301027A1 (es)
BR (1) BR112018001816A2 (es)
CA (1) CA2993882A1 (es)
CL (1) CL2018000231A1 (es)
MX (1) MX2018001135A (es)
WO (1) WO2017017048A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3584236A1 (en) * 2018-06-20 2019-12-25 Universitat de Barcelona Polycyclic compounds soluble epoxide hydrolase inhibitors
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
CN113185451B (zh) * 2021-04-28 2023-09-12 沈阳药科大学 美金刚脲类衍生物及其制备方法和应用
CN113402447B (zh) * 2021-06-22 2022-10-18 沈阳药科大学 一种sEH抑制剂或其药学上可接受的组合物及其制备方法和应用
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH456570A (de) * 1965-11-18 1968-07-31 Geigy Ag J R Verfahren zur Herstellung von neuen substituierten Harnstoffderivaten
US3621100A (en) * 1965-11-18 1971-11-16 Geigy Chem Corp Composition and method for producing a tuberculostatic effect
CA2559665A1 (en) * 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス， インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
CN101516838A (zh) * 2006-09-28 2009-08-26 亚瑞特医疗公司 可溶性环氧化物水解酶抑制剂

Also Published As

Publication number Publication date
US20200079786A1 (en) 2020-03-12
KR20180030706A (ko) 2018-03-23
CN108349955A (zh) 2018-07-31
WO2017017048A1 (en) 2017-02-02
CA2993882A1 (en) 2017-02-02
EP3328854A1 (en) 2018-06-06
CL2018000231A1 (es) 2018-07-20
BR112018001816A2 (pt) 2018-09-18
AU2016301027A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
MX2018001135A (es) Analogos de adamantilureas como inhibidores de epoxido hidrolasa soluble.
MY187479A (en) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12019502118A1 (en) Heterocyclic compounds useful as dual atx/ca inhibitors
PH12015502192A1 (en) Novel compounds
PH12019500811A1 (en) 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
RS51451B (en) PIRIDINE CARBOXAMIDES AS INHIBITORS OF 11-BETA-HSD1
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
TW200635585A (en) Monocyclic substituted methanones
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MY157116A (en) Novel seh inhibitors and their use
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
GB201103103D0 (en) Organic compounds
MY169179A (en) Novel piperidine compound or salt thereof
MX2022016515A (es) Nuevo inhibidor de la secrecion de acido y uso del mismo.
MX2010001005A (es) Derivados de (hetero)aril-metilen-n-cicloalquilcarboxamida condensados de 6 elementos con n como fungicidas.
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
PH12015502684A1 (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors